COVID-19 Vaccine Players Will Likely Split $40B in Profits: Analyst
August 13, 2020
By Neozene

This article originally appeared in FiercePharma and was written by Arlene Weintraub When longtime Evercore ISI pharma analyst Josh Schimmer realized that investors were struggling to place valuations on the leading COVID-19 vaccine developers, he pulled out the proverbial envelope, scribbled out some basic assumptions and issued predictions on Tuesday about just how profitable their endeavors might be. Schimmer’s numbers raised more than a few eyebrows, he reported today. The analyst predicted in a note that the total market for COVID-19 vaccines would be worth $100 billion in sales and

Read More

Johnson & Johnson Promises 100M Coronavirus Vaccine Doses
August 7, 2020
By Neozene

This article originally appeared in FiercePharma and was written by Eric Sagonowsky With leading COVID-19 vaccines in late-stage testing, companies have been inking supply deals with the U.S. government for a quick rollout if their programs succeed. Now, Johnson & Johnson is getting into the act. The pharma giant struck a deal to supply 100 million doses of its candidate, Ad26.COV2.S, if the shot is cleared for use by the FDA. The U.S. government is committing just over $1 billion under the agreement for a price per dose of about

Read More

Experts Fear Politics Will Cloud Vaccine Approval
July 29, 2020
By Neozene

This article originally appeared in FiercePharma and was written by Arthur Allen The vaccine trial that Vice President Mike Pence kicked off in Miami on Monday gives the United States the tiniest chance of being ready to vaccinate millions of Americans just before Election Day. It’s a possibility that fills many public health experts with dread. Among their concerns: Early evidence that any vaccine works would lead to political pressure from the administration for emergency approval by the Food and Drug Administration. That conflict between science and politics might cause

Read More